Quince Therapeutics, Inc. (QNCX) · Oct 19, 2026 · Other events
No new info
IRulya’s new corporate presentation recaps LAM-001’s pulmonary pipeline and trial milestones, but adds little beyond information already disclosed.
IRulya is now a pulmonary-focused clinical biotech building LAM-001, a once-daily inhaled rapamycin treatment across PH-ILD, BOS, and SAPH. Its Phase 2a PH study is complete, the BOS study is ongoing, PH-ILD development is advancing, and a SAPH study is expected in late 2026.
This 8-K is a communications refresh, not a new operating event. The filing says the company posted an updated corporate presentation dated October 2026.
The deck mainly repackages the existing clinical story and milestone calendar. The Phase 2a signals, ongoing BOS trial, PH-ILD Phase 2b program, and planned SAPH study were already disclosed in the company’s prior business updates and investor materials. The presentation reiterates that the BOS trial is fully enrolled with data anticipated in the first quarter of 2027.
There is no new efficacy readout, financing, regulatory decision, or changed guidance here. The presentation continues to frame LAM-001’s small open-label Phase 2a dataset as supportive, but the filing does not add blinded trial results or remove the clinical and funding risks already attached to the program.
Bottom line: This filing keeps IRulya’s renamed pulmonary-development story visible but does not materially change it. The next genuinely informative event is the BOS Phase 2 data expected in the first quarter of 2027.
BOS Phase 2 data, Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!